title: Novel pharmacological therapies for irritable bowel syndrome.
abstract: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder, which represents a major cost to healthcare services. Current pharmacological treatment includes fibre supplements, antispasmodics, laxatives, loperamide and antidepressants. This article reviews the novel pharmacological treatments already or recently approved for patients with IBS-C (lubiprostone, linaclotide) and IBS-D (alosetron, ramosetron, rifaximin, eluxadoline). Furthermore, results for drugs in development (plecanatide, ibudutant and ebastine) or used in chronic constipation or for other indications, with potential application in IBS (prucalopride, elobixibat, mesalazine, ondansetron and colesevelam) are also reviewed.
authors.affiliation: a Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven , Leuven , Belgium.
authors.forename: Maura
authors.initials: M
authors.lastname: Corsetti
authors.affiliation: b Centre for Gastrointestinal Sciences , University Manchester , Manchester , UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Whorwell
mesh_terms: D000818:Animals; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational; D005765:Gastrointestinal Agents
keywords: IBS treatment; constipation; diarrhea; pain